Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialization of Debio 0617
News Nov 21, 2008
Debiopharm Group and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based global biotech, signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialize Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
Utilizing its know-how and fragment-based drug delivery technology platform, Aurigene has generated potent leads against the target. Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones.
“We are very excited to continue our collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work. The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies,” said Rolland-Yves Mauvernay, President & Founder of Debiopharm Group.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019